

1 **Validation of multiplex steroid hormone measurements in prostate cancer using**
2 **plasma for multimodality biomarker studies**

3 Gido Snaterse^{1,a}, Lianne F van Dessel^{2,a}, Angela E Taylor³, Jenny A Visser¹, Wiebke Arlt³, Martijn P
4 Lolkema², Johannes Hofland^{1,*}

5 1. Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, The
6 Netherlands

7 2. Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The
8 Netherlands

9 3. Institute of Metabolism and System Research, University of Birmingham, Birmingham, United
10 Kingdom

11 ^aThese authors contributed equally to this work.

12 *Corresponding author

13 Address for correspondence: Johannes Hofland, Department of Internal Medicine, Erasmus MC, Rg5, Dr.
14 Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. Tel.: +31 10 704 0446.

15 E-mail: j.hofland@erasmusmc.nl

16

17 **Running title:** Multiplex steroid measurements in prostate cancer

18 **Key words:** Steroids, Androgens, Testosterone, CellSave, LC-MS/MS

19

21 **General Abbreviations**

22	ANOVA	Analysis of variance
23	CRPC	Castration resistant prostate cancer
24	CS	CellSave Preservative tube
25	CTC	Circulating tumour cell
26	ctDNA	circulating tumour DNA
27	HC	Healthy Control
28	LC-MS/MS	Liquid chromatography tandem mass spectrometry
29	LOQ	Limits of quantification
30	MS	Mass spectrometry
31	MSP	Mechanically separated plasma tube
32	MTBE	Methyl-tert butyl ether
33	PC	Prostate cancer
34	S/N	Signal-to-noise
35	PBS-BSA	phosphate-buffered saline with bovine serum albumin

36 **Steroid abbreviations**

37	17OHP	17-hydroxyprogesterone
38	A4	Androstenedione
39	B	Corticosterone
40	DHEA	Dehydroepiandrosterone
41	DHT	Dihydrotestosterone
42	E	Cortisone
43	F	Cortisol
44	T	Testosterone

45 **ABSTRACT**

46 **Background**

47 Steroid hormones are essential signaling molecules in prostate cancer (PC). However, many studies
48 focusing on liquid biomarkers fail to take hormonal status of these patients into account. Because
49 steroid measurements are sensitive to bias caused by matrix effects, thus assessing potential matrix
50 effects is an important step in combining ctDNA analysis with hormone status.

51 **Methods**

52 We investigated the accuracy of multi-steroid hormone profiling in mechanically-separated plasma
53 tubes (MSP) and in CellSave Preservative plasma tubes (CS), that are typically used to obtain ctDNA. We
54 performed multiplex steroid profiling in samples obtained from ten healthy controls and ten castration-
55 resistant prostate cancer patients

56 **Results**

57 Steroid measurements were comparable between the MSP and serum tubes. A small but consistent
58 decrease of 11 – 18% compared to serum was observed in CS tubes, which was considered to be within
59 the acceptable margin. The minimally residual testosterone levels of castrate patients could be
60 sensitively quantified in both CS and MSP samples.

61 **Conclusions**

62 We validated the use of MSP and CS tubes for multi-steroid profiling by LC-MS/MS. The optimised use of
63 these samples used in clinical trials will allow us to gain further insight into the steroid metabolism in PC
64 patients.

65 **INTRODUCTION**

66 Prostate cancer is a steroid-hormone dependent disease where androgens play a pivotal role in the
67 evolution of the disease. Targeting the androgen signaling pathway through androgen deprivation
68 therapy (ADT) in locally advanced and metastatic prostate cancer is a highly effective way to inhibit
69 tumour growth¹. However, tumour cells will eventually become resistant to these low androgen
70 concentrations and show disease progression. Resistance mechanisms include androgen receptor (AR)
71 modifications, like mutations and overexpression^{2,3}, and changes in androgen biosynthesis and
72 metabolism, thereby increasing intratumoural androgen availability⁴⁻⁶. The continued importance of the
73 androgen signaling pathway in castration-resistant prostate cancer (CRPC) is underlined by the survival
74 benefits observed with second-line therapies such as the anti-androgen enzalutamide and adrenal
75 steroidogenesis inhibitor abiraterone⁷⁻¹⁰. Circulating steroid levels are measured to verify efficacy of
76 hormonal treatment and have a prognostic value in patients with prostate cancer¹¹⁻¹³.

77 The assessment of circulating steroid hormones relies heavily on sensitive, specific and accurate
78 measurement techniques, especially at castrate levels. Liquid-chromatography tandem mass
79 spectrometry (LC-MS/MS) combines multi-steroid profiling capabilities with superior sensitivity and
80 specificity^{14,15} over older techniques^{16,17}, while maintaining high sample throughput^{18,19}. Extensive MS-
81 based steroid panels have been successfully developed in recent years to improve the detection and
82 diagnosis of disorders associated with abnormal steroid hormones concentrations²⁰⁻²³.

83 Steroid measurements are predominantly performed in serum samples. Previous LC-MS/MS studies
84 have shown that steroids can be quantified reliably across different blood matrices²⁴⁻²⁶, but there are
85 differences observed between plasma and serum, glass and plastic tubes, or when using tubes with
86 different stabilizing agents or with gel-separators²⁴⁻²⁹. Consequently, alternative collection tubes and
87 extraction methods must be validated before they can reliably be used for steroid profiling.

88 The use of CellSave (CS) tubes in population- and patient-based cohorts has grown as this specialised
89 'cell-stabilizing' blood collection tube preserves both circulating tumour cells (CTCs) and cell-free
90 circulating tumour DNA (ctDNA)^{30,31}. These biomarkers allow for the assessment of tumour cell genomic
91 characteristics such as genomic instability in these patients³². These samples are now extensively
92 collected in (cancer) biobanks and could potentially also be used to measure patient steroid profiles.

93 Mechanical separation methods of blood are similarly gaining popularity in clinical chemistry due to
94 their easy applicability compared to those that use a separation gel. The BD Vacutainer Barricor is a
95 mechanically-separated plasma (MSP) tube, and it has shown no obvious bias in steroid hormone
96 measurements versus a gel-based plasma tube in a single study³³, but this was confined to a select
97 number of five steroids, warranting further investigation.

98 Previous studies have identified matrix effects, interference caused by a contaminant from serum or
99 collection tube that leads to false high or low quantification, as a potential source of bias^{25,26,28}, and it is
100 therefore imperative to assess the quality of steroid measurements in CS tubes and MSP tubes. In this
101 study, we aimed to determine if plasma obtained with these tubes is suitable for multiplex steroid
102 profiling. To this end, we performed LC-MS/MS analysis on serum obtained with standard SST™ II
103 Advance Vacutainer® tubes and plasma samples obtained with MSP and CS tubes from healthy control
104 (HC) subjects and patients with CRPC.

105 RESULTS

106 Comparison of blood collection tubes

107 Baseline characteristics of the study participants are shown in **Table 1**. Circulating steroid levels of 16
108 steroids were determined by LC-MS/MS in 10 HCs and 10 mCRPC patients in all three collection tubes.
109 Quantification and concentration ranges for the steroids are reported in **Table 2**. Most steroids could be
110 quantified in healthy controls at the level of the lowest calibration sample (0.25 ng/ml), with the
111 exception of androstenedione (0.5 ng/ml), DHEA (1 ng/ml) and DHT (1 ng/ml). Serum DHEA values
112 below the LLOQ were detected (HC: n =1, CRPC: n = 4) and excluded from further analysis.

113 The values observed in MSP samples were comparable to those found in serum for most steroids. The
114 only exception was DHEA, which was higher ($21.3 \% \pm 32.9 \% p < 0.05$) in the MSP samples than in serum
115 (**Figure 1**). In CS samples, significantly lower concentrations compared to serum were observed for
116 corticosterone ($-16.2 \% \pm 15.2 \% , p < 0.01$), 17-hydroxyprogesterone ($-11.0 \% \pm 20.03 \% , p < 0.05$), cortisol
117 ($-13.2 \% \pm 13.0 \% , p < 0.001$), cortisone ($-14.4 \% \pm 13.1 \% , p < 0.001$), androstenedione ($-18.4 \% \pm 13.6 \% ,$
118 $p < 0.01$). No significant differences were found for DHEA compared to serum.

119 Similar steroid concentrations between HC and mCRPC subjects were observed for corticosterone,
120 cortisol and cortisone (**Figure 2**). Lower concentrations were observed for 17-hydroxyprogesterone,
121 androstenedione and testosterone in mCRPC subjects. This was likely due to a combination of castration
122 (testosterone) and age-related effects, as the mCRPC subjects were older than those the healthy control
123 subjects.

124 Androgen levels in mCRPC patients are >10 fold lower than in healthy men due to ADT, requiring
125 sensitive techniques to accurately measure residual androgens. The calibration series was expanded to
126 include lower concentrations (0.01 – 0.25 ng/ml) to allow quantification of castrate testosterone levels.

127 Accurate quantification at 0.01 ng/mL was achieved for testosterone. Similar to the other steroids, lower
128 testosterone concentrations compared to serum were detected in CS samples, but not in MSP samples,
129 at normal HC concentrations ($-11.5\% \pm 2.8\%$, $p < 0.001$) and at castrate concentrations ($-16.9\% \pm 24.2\%$,
130 $p < 0.05$) (**Figure 1**). Low signal-to-noise ratios limited the reliability of DHT quantification which could not
131 be accurately quantified in the CRPC subjects with our assay.

132 **Correlation of steroid measurements between matrices**

133 The correlations between results obtained MSP and CS samples, respectively, compared to those
134 obtained in serum were determined by linear regression (**Figure 3**). For the DHT analysis only HC
135 samples were included. Corticosterone, DHEA and testosterone were normally distributed after log-
136 transformation. Significant correlation ($p < 0.001$) between both matrices and serum was observed for
137 corticosterone, 17-hydroxyprogesterone, cortisol, DHEA and testosterone. High correlation was also
138 observed for cortisone and androstenedione, but with a more than 20% deviation from the optimal
139 slope ($p < 0.05$) with the CS matrix: both 0.79x. The analysis also revealed a poor correlation for DHT
140 between CS and serum ($R^2 = 0.60$) and between MSP and serum ($R^2 = 0.45$).

141

142 DISCUSSION

143 In this study, we investigated whether collected samples that are abundantly present in biobanks
144 obtained from PC patients such as mechanically separated plasma or CS-derived plasma are suitable for
145 multiplex steroid profiling by LC-MS/MS. We compared them to the current standard collection method
146 using SST™ II Advance Vacutainers. We showed that measurements in MSP are equal to serum. When
147 collecting in CS tubes 11-18% lower concentrations were observed for all steroids. The Guideline on
148 Bioanalytical Method Validation (2011) of the European Medicines Agency advises that accuracy must
149 be within 15 % of the nominal concentration and within 20 % at the LLOQ³⁴. The decreases observed for
150 most steroids in CS tubes using serum as a reference were within this acceptable range (**Table 2**).
151 Therefore, we conclude that CS samples are suitable for steroid profiling, which can be combined with
152 analysis of CTCs or ctDNA. However, caution is advised when interpreting results obtained in CS samples
153 against reference values that were obtained in serum, and direct comparison to samples collected in
154 other tubes should be avoided. Nevertheless, these findings may reduce patient burden and open up
155 the possibility to add detailed steroid profiling of large collections of biomaterial already collected for
156 ctDNA analysis.

157 In this study, most steroids could be quantified accurately within the range of the calibration series.
158 Most of the Δ 4-steroids, such as cortisol or testosterone, ionise more easily and so can be accurately
159 quantified at low levels (0.03 – 0.15 nM). This allows for the quantification of testosterone in mCRPC
160 patients (typically <0.5nM)¹¹. Δ 5-steroids such as DHEA and saturated steroids such as DHT are poor
161 ionisers and quantification at lower concentrations is beyond the sensitivity of the mass spectrometer²².
162 Like testosterone, DHT levels are suppressed in castrated patients and the concentrations in these
163 patients could not be accurately assessed. DHEA levels in men decline with age³⁵, and the mCRPC
164 subjects in this study were older than the HC subjects. Consequently, values below the LLOQ were

165 detected in four CRPC patients and were excluded from the analysis. Derivatization, for example to form
166 an oxime, increases ionizability, and therefore sensitivity allowing low level quantification of $\Delta 5$ - and 5 α -
167 reduced steroids²². However, the derivatization method is not suited for routine clinical diagnostic
168 measurements due to increased sample preparation time and cost. In addition to this, fragmentation
169 produces multiple derivatives for some steroids adding to the complexity of the analysis.

170 Matrix effects and cross-reactivity are established sources of interference in steroid hormone profile
171 studies with immunoassay and LC-MS/MS²⁴⁻²⁹. Previous studies have identified the type of blood sample
172 tube as a potential source of interference. MSP tubes like BD Vacutainer Barricor utilise mechanical
173 separation which makes them easily applicable, but the accuracy of steroid hormone measurements in
174 these tubes has not been validated. One study³³ showed no differences to gel-based plasma tubes, but
175 these measurements were performed on a single platform with a limited number of steroids, namely
176 cortisol, DHEAS, oestradiol, progesterone, and testosterone. Our study shows that multi-plex steroid
177 quantification in MSP sample tubes is comparable to the reference serum tubes. We detected no
178 significant differences, with the exception of DHEA. This seemed to be largely driven by samples in the
179 HC group. Quantification of DHEA at low concentrations with LC-MS/MS remains a challenge as its
180 structure contributes to poor MS ionization^{22,36}. This challenge could be overcome by using a more
181 sensitive mass spectrometer or with the use of derivatization. Prior to using MSP tubes for clinical
182 studies however, full validation looking at accuracy, precision and recovery is recommended.

183 CS tubes are optimised for the measurement of circulating nucleic acids or tumour cells^{30,31}. The use of
184 this matrix for liquid biopsies has increased exponentially over the last years due to the successful
185 genomic characterization of CTCs or free circulating nucleic acids, but no studies have investigated if CS
186 tubes are suitable for quantification of circulating steroid hormone levels. Our experiments indicate that
187 steroid measurements in CS tubes are affected by a mild bias which resulted in an approximate 10 – 20%

188 decrease compared to serum. We observed similar effects in both HCs and mCRPC subjects. CS tubes
189 contain 300 μ l of Na₂EDTA anticoagulant as well as an undisclosed preservative to stabilise cells in the
190 sample. Due to the presence of the Na₂EDTA there may be an inherent dilution of the sample, which
191 amounts to approximately 3-4 % on a 7.5 – 10 ml volume. This dilution factor is insufficient to account
192 for the difference in circulating steroid hormone levels however. Consequently, it is possible that other
193 factors also contribute towards the observed difference.

194 This decrease was observed across a variety of different polarity steroids with different molecular
195 weights. It is therefore unlikely that the preservative co-elutes with one of the steroids and suppresses
196 the MS signal. Either there is an unidentified contaminant in the tubes which affects all steroids or the
197 steroids themselves are being retained/bind to the tube itself. Steroids have been long recognised to
198 stick to plastics³⁷, which may contribute to the lower values in CS samples.

199 Currently, CS tubes are most commonly utilised in oncological studies to obtain CTCs and ctDNA.
200 Hormonal treatment options in breast and prostate cancer involve potent suppression of oestrogens or
201 androgens. For example, inhibition of testicular steroidogenesis by ADT will typically lower testosterone
202 levels by >90 %¹¹. Interpretation of such changes is unlikely to be affected by the difference observed in
203 CS samples. Especially within the context of a single study the relative difference should affect all
204 samples identically as long as a single collection tube is used. As such, the observed difference is
205 acceptable for most clinical purposes, including the use of CS samples for steroid profiling in prostate
206 cancer patients. Steroid profiles and analysis of CTCs or ctDNA investigation will decrease costs and
207 reduce patient burden.

208 In conclusion, mechanically-separated plasma samples are suitable for steroid quantification, including
209 castrate range of androgens. Similarly, CellSave samples are suitable for steroid measurements,
210 although there is a consistent bias of –11-18% lower steroid hormone levels. Because of this, all samples

211 in a research study should be collected in the same sample tubes to avoid potential variation due to
212 effects from the tubes themselves.

213 **MATERIALS AND METHODS**

214 *Subjects*

215 At the Erasmus MC Cancer Institute in Rotterdam, The Netherlands, healthy controls (HCs) and patients
216 were included within study EMC-2016-761, which was approved by the medical ethical committee of
217 our institute. HCs were all adult male subjects. Patients were adult subjects with metastatic castration-
218 resistant prostate cancer (mCRPC), treated with ADT. Patients were eligible to start treatment with or
219 were currently treated with second-line hormonal therapy (abiraterone with prednisone, enzalutamide
220 or apalutamide). For all subjects the following exclusion criteria were applied: 1) endocrine disease with
221 altered activity of the hypothalamic-pituitary-adrenal or hypothalamic-pituitary-gonadal axis; 2) the use
222 of medications, excluding those used to treat prostate cancer, that interfered with circulating steroid
223 levels or dysregulated the hypothalamic-pituitary-adrenal or hypothalamic-pituitary-gonadal axis. All
224 subjects provided written informed consent before any study procedure.

225 *Samples*

226 Blood was collected from HCs and mCRPC patients in SST™ II Advance Vacutainer® (serum; BD, Franklin
227 Lakes, NJ, USA), Barricor Vacutainer® (BD) and CellSave Preservative (Menarini Silicon Biosystems Inc,
228 Huntington Valley, PA, USA) blood collection tubes. All samples were processed within 96 hours after
229 blood collection. All tubes were centrifuged at 1,711g for 10 minutes at room temperature. Plasma from
230 CellSave tubes was subsequently centrifuged at 12,000g for 10 minutes at 4°C. Samples were stored at -
231 80°C until extraction.

232

233 *Steroid extraction*

234 Calibration series (0.25 ng/ml – 500 ng/ml for HC, and 0.01 ng/ml – 500 ng/ml for mCRPC) were
235 prepared in phosphate buffered saline (PBS) with 0.1% bovine serum albumin (BSA) or in charcoal-
236 stripped pooled human serum (Goldenwest Diagnostics, Temecula, CA, USA). Steroids investigated were
237 17-hydroxyprogesterone, androstenedione, cortisol, cortisone, corticosterone, dehydroepiandrosterone
238 (DHEA), dihydrotestosterone (DHT) and testosterone. The stripped-serum calibration series was used to
239 quantify all steroids with the exception of androstenedione, due to a high background signal in stripped
240 serum but not in PBS-BSA. An internal standard solution was prepared in methanol/water 50/50 with
241 equal concentrations (1 µg/ml) of the following deuterated steroids: 17-hydroxyprogesterone-d8,
242 cortisol-d4, corticosterone-d8, DHEA-d6, DHT-d3, testosterone-d3. All steroids were obtained from
243 Sigma Aldrich, UK.

244 400 µl of sample was transferred to hexamethyldisilazane-treated (Thermo Fisher) glass tubes (VWR,
245 Amsterdam, The Netherlands). 20 µl of the internal standard solution was added and all samples were
246 thoroughly vortexed. Liquid-liquid extraction was performed by adding 2 ml methyl-tert butyl ether
247 (MTBE, Sigma Aldrich, Zwijndrecht, The Netherlands) to each tube and vortexing. The samples were left
248 at room temperature for 30 minutes to allow phase separation. The upper organic layer was transferred
249 and the MTBE was evaporated under nitrogen at 50° C. The samples underwent a second liquid-liquid
250 extraction with 2 ml MTBE. Samples were reconstituted in 125 µl LC-MS grade 50% methanol
251 (CHROMASOLV, Sigma Aldrich, Zwijndrecht, The Netherlands) before measurement.

252

253 *LC-MS/MS*

254 Steroid concentrations were measured by mass spectrometry (Xevo TQ-XS, Waters, Milford, MA, USA)
255 after separation on an ACQUITY uPLC (Waters) with a Waters HSS T3 column (2.1 mm x 50 mm, 1.8 μ m,
256 Waters)³⁸⁻⁴³. The mobile phases consisted of water (A) and methanol (B) both with 0.1% formic acid and
257 a 5-minute linear gradient was used (45 – 75% B) with a flow rate of 0.6 ml/min. The multiple reaction
258 monitoring settings and validation of these LC-MS/MS methods were previously reported^{38,42}. Steroids
259 were quantified against the linear calibration series relative to an internal standard and were only
260 included in the final analysis if the calibration series R^2 was > 0.99 and appropriate lower limits of
261 quantification were reached. The lower limit of accurate quantification (LLOQ) was set to the lowest
262 calibration concentration that had a clearly defined peak and a signal-to-noise ratio > 10. Samples with
263 concentrations below the LLOQ were detectable, but not accurately quantifiable.

264 *Statistics*

265 LC-MS/MS raw data was processed using MassLynx (v4.1, Waters). Statistical analysis was performed
266 using GraphPad Prism (Version 5). Normality of data was analysed with D'Agostino & Pearson's test.
267 Comparisons of steroid hormone concentrations across the blood collection tubes were performed with
268 repeat measurements 1-way ANOVA with post-hoc Dunnett's test. Correlations in hormone levels were
269 determined by linear regression. Group concentrations and differences are shown as mean \pm SD, unless
270 specified otherwise. P values were considered significant if <0.05.

271 **Data Availability**

272 The datasets generated during and/or analysed during the current study are available from the
273 corresponding author on reasonable request.

274 **References**

- 275 1 Sharifi, N., Gulley, J. L. & Dahut, W. L. Androgen deprivation therapy for prostate cancer. *JAMA*
276 **294**, 238-244 (2005).
- 277 2 Linja, M. J. *et al.* Amplification and overexpression of androgen receptor gene in hormone-
278 refractory prostate cancer. *Cancer Res* **61**, 3550-3555 (2001).
- 279 3 Taylor, B. S. *et al.* Integrative genomic profiling of human prostate cancer. *Cancer Cell* **18**, 11-22
280 (2010).
- 281 4 Stanbrough, M. *et al.* Increased expression of genes converting adrenal androgens to
282 testosterone in androgen-independent prostate cancer. *Cancer Res* **66**, 2815-2825 (2006).
- 283 5 Montgomery, R. B. *et al.* Maintenance of intratumoral androgens in metastatic prostate cancer:
284 a mechanism for castration-resistant tumor growth. *Cancer Res* **68**, 4447-4454 (2008).
- 285 6 Mohler, J. L. *et al.* The androgen axis in recurrent prostate cancer. *Clin Cancer Res* **10**, 440-448
286 (2004).
- 287 7 Scher, H. I. *et al.* Increased survival with enzalutamide in prostate cancer after chemotherapy. *N*
288 *Engl J Med* **367**, 1187-1197 (2012).
- 289 8 de Bono, J. S. *et al.* Abiraterone and increased survival in metastatic prostate cancer. *N Engl J*
290 *Med* **364**, 1995-2005 (2011).
- 291 9 Fizazi, K. *et al.* Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
292 *N Engl J Med* **377**, 352-360 (2017).
- 293 10 Davis, I. D. *et al.* Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. *N*
294 *Engl J Med* **381**, 121-131 (2019).
- 295 11 Snaterse, G., Visser, J. A., Arlt, W. & Hofland, J. Circulating steroid hormone variations
296 throughout different stages of prostate cancer. *Endocr Relat Cancer* **24**, R403-R420 (2017).

- 297 12 Sakamoto, S. *et al.* Higher Serum Testosterone Levels Associated with Favorable Prognosis in
298 Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer. *J Clin Med* **8**
299 (2019).
- 300 13 Attard, G. *et al.* Selective inhibition of CYP17 with abiraterone acetate is highly active in the
301 treatment of castration-resistant prostate cancer. *J Clin Oncol* **27**, 3742-3748 (2009).
- 302 14 Wang, C., Catlin, D. H., Demers, L. M., Starcevic, B. & Swerdloff, R. S. Measurement of total
303 serum testosterone in adult men: comparison of current laboratory methods versus liquid
304 chromatography-tandem mass spectrometry. *J Clin Endocrinol Metab* **89**, 534-543 (2004).
- 305 15 Taieb, J. *et al.* Testosterone measured by 10 immunoassays and by isotope-dilution gas
306 chromatography-mass spectrometry in sera from 116 men, women, and children. *Clin Chem* **49**,
307 1381-1395 (2003).
- 308 16 Handelsman, D. J. *et al.* Performance of direct estradiol immunoassays with human male serum
309 samples. *Clin Chem* **60**, 510-517 (2014).
- 310 17 Krasowski, M. D. *et al.* Cross-reactivity of steroid hormone immunoassays: clinical significance
311 and two-dimensional molecular similarity prediction. *BMC Clin Pathol* **14**, 33 (2014).
- 312 18 Taylor, A. E., Keevil, B. & Huhtaniemi, I. T. Mass spectrometry and immunoassay: how to
313 measure steroid hormones today and tomorrow. *Eur J Endocrinol* **173**, D1-12 (2015).
- 314 19 Monaghan, P. J., Keevil, B. G. & Trainer, P. J. The use of mass spectrometry to improve the
315 diagnosis and the management of the HPA axis. *Rev Endocr Metab Disord* **14**, 143-157 (2013).
- 316 20 Arlt, W. *et al.* Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary
317 aldosteronism. *JCI Insight* **2** (2017).
- 318 21 Arlt, W. *et al.* Urine steroid metabolomics as a biomarker tool for detecting malignancy in
319 adrenal tumors. *J Clin Endocrinol Metab* **96**, 3775-3784 (2011).

- 320 22 Hakkinen, M. R. *et al.* Simultaneous analysis by LC-MS/MS of 22 ketosteroids with
321 hydroxylamine derivatization and underivatized estradiol from human plasma, serum and
322 prostate tissue. *J Pharm Biomed Anal* **164**, 642-652 (2019).
- 323 23 Storbeck, K. H. *et al.* Steroid metabolome analysis in disorders of adrenal steroid biosynthesis
324 and metabolism. *Endocr Rev* (2019).
- 325 24 Coburn, S. B. *et al.* Comparability of serum, plasma, and urinary estrogen and estrogen
326 metabolite measurements by sex and menopausal status. *Cancer Causes Control* **30**, 75-86
327 (2019).
- 328 25 Hepburn, S. *et al.* Sex steroid hormone stability in serum tubes with and without separator gels.
329 *Clin Chem Lab Med* **54**, 1451-1459 (2016).
- 330 26 Raff, H. & Sluss, P. M. Pre-analytical issues for testosterone and estradiol assays. *Steroids* **73**,
331 1297-1304 (2008).
- 332 27 Morovat, A. *et al.* Comparison of Bayer Advia Centaur immunoassay results obtained on samples
333 collected in four different Becton Dickinson Vacutainer tubes. *Ann Clin Biochem* **43**, 481-487
334 (2006).
- 335 28 Smets, E. M., Dijkstra-Lagemaat, J. E. & Blankenstein, M. A. Influence of blood collection in
336 plastic vs. glass evacuated serum-separator tubes on hormone and tumour marker levels. *Clin*
337 *Chem Lab Med* **42**, 435-439 (2004).
- 338 29 Schouwers, S. *et al.* Influence of separator gel in Sarstedt S-Monovette(R) serum tubes on
339 various therapeutic drugs, hormones, and proteins. *Clin Chim Acta* **413**, 100-104 (2012).
- 340 30 Rothwell, D. G. *et al.* Genetic profiling of tumours using both circulating free DNA and circulating
341 tumour cells isolated from the same preserved whole blood sample. *Mol Oncol* **10**, 566-574
342 (2016).

- 343 31 van Dessel, L. F. *et al.* Application of circulating tumor DNA in prospective clinical oncology trials
344 - standardization of preanalytical conditions. *Mol Oncol* **11**, 295-304 (2017).
- 345 32 van Dessel, L. F. *et al.* The genomic landscape of metastatic castration-resistant prostate cancers
346 reveals multiple distinct genotypes with potential clinical impact. *Nat Commun* **10**, 5251 (2019).
- 347 33 Fournier, J. E. *et al.* Evaluation of BD Vacutainer(R) Barricor blood collection tubes for routine
348 chemistry testing on a Roche Cobas(R) 8000 Platform. *Clin Biochem* **58**, 94-99 (2018).
- 349 34 European Medicines Agency. Guideline on Bioanalytical Method Validation. (2011).
- 350 35 Kaufman, J. M. & Vermeulen, A. The decline of androgen levels in elderly men and its clinical and
351 therapeutic implications. *Endocr Rev* **26**, 833-876 (2005).
- 352 36 Keski-Rahkonen, P., Huhtinen, K., Poutanen, M. & Auriola, S. Fast and sensitive liquid
353 chromatography-mass spectrometry assay for seven androgenic and progestagenic steroids in
354 human serum. *J Steroid Biochem Mol Biol* **127**, 396-404 (2011).
- 355 37 Bruning, P. F., Jonker, K. M. & Boerema-Baan, A. W. Adsorption of steroid hormones by plastic
356 tubing. *J Steroid Biochem* **14**, 553-555 (1981).
- 357 38 O'Reilly, M. W. *et al.* A unique androgen excess signature in idiopathic intracranial hypertension
358 is linked to cerebrospinal fluid dynamics. *JCI Insight* **4** (2019).
- 359 39 Buttler, R. M. *et al.* Comparison of 7 Published LC-MS/MS Methods for the Simultaneous
360 Measurement of Testosterone, Androstenedione, and Dehydroepiandrosterone in Serum. *Clin*
361 *Chem* **61**, 1475-1483 (2015).
- 362 40 van der Pas, R. *et al.* Fluconazole inhibits human adrenocortical steroidogenesis in vitro. *J*
363 *Endocrinol* **215**, 403-412 (2012).
- 364 41 Hassan-Smith, Z. K. *et al.* Gender-Specific Differences in Skeletal Muscle 11beta-HSD1 Expression
365 Across Healthy Aging. *J Clin Endocrinol Metab* **100**, 2673-2681 (2015).

366 42 Quanson, J. L. *et al.* High-throughput analysis of 19 endogenous androgenic steroids by ultra-
367 performance convergence chromatography tandem mass spectrometry. *J Chromatogr B Analyt*
368 *Technol Biomed Life Sci* **1031**, 131-138 (2016).

369 43 O'Reilly, M. W. *et al.* 11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic
370 Ovary Syndrome. *J Clin Endocrinol Metab* **102**, 840-848 (2017).

371

372

373 **Acknowledgements**

374 Funding for this project was provided by the Daniel den Hoed foundation.

375 The authors thank the volunteers and patients who made this study possible.

376 **Author Information**

377 These authors contributed equally: Gido Snaterse and Lisanne F van Dessel.

378 **Author Contributions**

379 G.S. performed the LC-MS/MS experiments, data analysis, prepared figures/tables and wrote the
380 manuscript. L.F.D. collected the patient samples, performed data analysis, prepared figures/tables and
381 wrote the manuscript. A.E.T. oversaw the LC-MS/MS experiments and analysis of the data, and critical
382 revision of the manuscript. W.A. was involved in interpretation of the data and critical revision of the
383 manuscript. M.P.L. was involved in the design of the work, collection of the samples and critical revision
384 of the manuscript. J.A.V and J.H. were involved in the design of the work, interpretation of the data,
385 critical revision of the manuscript.

386 All authors reviewed and approved the final version of the manuscript.

387 **Corresponding author**

388 Correspondence to Johannes Hofland.

389 **Conflict of Interest**

390 M. P. L. is the recipient of grants of Sanofi, Johnson & Johnson and Astellas. Other authors did not
391 declare a conflict of interests.

392

393 **Table 1 – Characteristics of healthy controls and castration-resistant prostate cancer patients**

394 Abbreviations: mCRPC – metastatic castration-resistant prostate cancer

	Healthy Controls	mCRPC patients
N	10	10
Age (median (range))	32 (25 - 56)	64 (59 - 76)
Androgen Deprivation Therapy (n)		10
Leuproreline		4
Gosereline		4
Bilateral orchiectomy		2
Current second-line treatment (n)		6
Enzalutamide		3
Apalutamide		1
Abiraterone + Prednisone		1
Prednisone		1

395

396 **Table 2 – Relative differences in CS and MSP tubes compared to SST™ II Advance Vacutainers.**

397 Relative differences are shown as mean ± SD. Statistical analysis was performed by repeated
398 measurement 1-way ANOVA with post-hoc Dunnett’s Test. *p<0.05, ** p<0.01, ***p<0.001.

399 Abbreviations: CS – CellSave Preservative, DHEA – dehydroepiandrosterone, DHT – dihydrotestosterone,
400 HC – Healthy Control, mCRPC – metastatic castration-resistant prostate cancer, MSP – mechanically
401 seperated plasma tube

	Healthy Controls (n = 10)			mCRPC (n = 10)		
	Serum Range nmol/L	CS Rel. Difference mean (SD) %	MSP Rel. Difference mean (SD) %	Serum Range nmol/L	CS Rel. Difference mean (SD) %	MSP Rel. Difference mean (SD) %
Corticosterone	2.32 - 32.71	-20.08 (16.6) **	2.6 (11)	0.55 - 25.34	-12.3 (13.3) *	-2.8 (9.8)
17-hydroxyprogesterone	0.37 - 3.75	-14.4 (15.3) *	3.16 (16.26)	0.05 - 1.75	-7.6 (24.22)	-2.3 (16.58)
Cortisol	149.1 - 475.7	-13.7 (6.1) ***	-0.14 (3.5)	7.43 - 504.6	-12.7 (17.9) **	-1.3 (16.1)
Cortisone	36.35 - 79.4	-10.8 (6.3) ***	-2 (9.2)	0.1 - 80.81	-17.9 (17.2) **	-1.5 (10.5)
DHEA	0.69 - 36.14	-0.17 (18.8)	28.7 (46.6)*	<LOQ - 1.7	-17.7 (16.5)	6.0 (12.2)
Androstenedione	2.33 - 6.05	-15.85 (13.5) **	6.9 (9.5)	0.48 - 3.19	-21.2 (14.01) **	6.34 (10.4)
Testosterone	7.47 - 17.74	-11.48 (2.8) ***	0.82 (4.7)	0.06 - 0.78	-19.6 (28.2) *	-3.5 (33.3)
DHT	0.66 - 1.64	-11.26 (29.2)	-3.5 (30.4)	<LOQ	<LOQ	<LOQ


402

403

404 **Figure 1. CS and MSP samples compared to serum in healthy controls and mCRPC patients.**

405 Steroid concentrations from serum, CS and MSP samples obtained from ten healthy controls and ten
406 mCRPC patients measured by LC-MS/MS. Relative difference of CS and MSP measurements compared to
407 serum is shown. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, compared to serum matrix. Repeated Measurements
408 1-way ANOVA with post-hoc Dunnett's Test.

409 Abbreviations: CS – CellSave Preservative, DHEA – dehydroepiandrosterone, HC – Healthy Control,
410 mCRPC – metastatic castration-resistant prostate cancer, MSP – mechanically seperated plasma tube




411

412

413 **Figure 2 – Circulating steroid concentrations in healthy controls and mCRPC subject serum.**

414 Steroid hormone concentrations in healthy controls (n = 10) and mCRPC patients (n = 10). Four patients
415 received no additional treatment, four received antiandrogens (enzalutamide (n=3) or apalutamide
416 (n=1)), one received abiraterone and prednisone and one received prednisone. Line and error represent
417 mean \pm SEMs.

418 *Abbreviations:* 17OHP – 17-hydroxyprogesterone, A4 – androstenedione, B – corticosterone, DHEA –
419 dehydroepiandrosterone, CRPC – castration-resistant prostate cancer, E – cortisone, F – cortisol, T –
420 testosterone



421

422 **Figure 3 – Correlations between CS samples and MSP samples with serum.**

423 Linear regression analysis between serum and CellSave measurements and between serum and MSP
424 measurements in healthy controls and mCRPC patients combined. Corticosterone, DHEA and
425 testosterone values did not pass normality testing (D’Agostino and Pearson), but did so after logarithmic
426 transformation. *Abbreviations:* CS – CellSave Preservative Tube, DHEA – dehydroepiandrosterone, MSP –
427 mechanically separated plasma tube.

